F
Author

fgalzin

111 Articles

Articles by fgalzin

PLG
June 13, 2023
English
UK National Contact Person for Pharmacovigilance next-arrow
PLG
June 02, 2023
English
Overcoming Challenges in the Chinese Pharmaceutical Clients: How PLG Solutions Support Client Success next-arrow
CEP 2.0: The Future of Certification of Suitability to the European Pharmacopoeia
May 23, 2023
English
CEP 2.0: The Future of Certification of Suitability to the European Pharmacopoeia next-arrow
Understanding the Nordic market
May 11, 2023
English
Understanding the Nordic market next-arrow
PLG
May 10, 2023
English
Market access: implications of the regional convergence trend on Biopharma and Medtech next-arrow
EU affiliate landscape... A complex web
May 09, 2023
English
EU affiliate landscape... A complex web next-arrow
PLG
April 25, 2023
English
Industry bodies commented on USFDA released M11: technical specification - clinical electronic structured harmonized protocol (CESHARP) next-arrow
PLG
April 25, 2023
English
USFDA Guidance released! For Product-Specific Guidance Meetings for the ANDA applicants next-arrow
PLG
April 20, 2023
English
Responsibilities of the marketing authorization holder concerning the qualified person responsible for pharmacovigilance (QPPV) in the EU next-arrow
Periodic Adverse Drug Experience Report (PADER) in a nutshell
April 20, 2023
English
Periodic Adverse Drug Experience Report (PADER) in a nutshell next-arrow
PLG
April 11, 2023
English
ProductLife Consulting C-Level Event next-arrow
PLG
March 28, 2023
English
Differences in registration requirements for Europe and US market next-arrow
PLG
March 28, 2023
English
General Cross functional PV collaboration next-arrow
PLG
March 07, 2023
English
Clinical Trials Information System for Clinical Trial Applications in Europe next-arrow
PLG stands on Zero Discrimination Day
February 28, 2023
English
PLG stands on Zero Discrimination Day next-arrow
Back 1 2 3 4 5 6 7 8 Next